v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
| Column | Value |
|---|---|
| Trial registration number | NCT04928495 |
|
Full text link
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
|
|
First author
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
|
|
Contact
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Not reported |
|
Registration date
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
2021-06-16 |
|
Recruitment status
Last imported at : June 4, 2023, 4 a.m. Source : ClinicalTrials.gov |
Unknown |
|
Study design
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
RCT |
|
Allocation
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Randomized |
|
Design
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Parallel |
|
Masking
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Blind label |
|
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
|
Study aim
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Treatment |
|
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
the inclusion criteria will be: patients with clinical signs and symptoms of covid-19; and patients over 18 years and below 60 years of age. the exclusion criteria will be: participate in another clinical intervention study; you have a disease or other medical condition that prevents you from using the medications for this intervention; patient incapable of ingesting, retaining and absorbing the intervention medications; and (d) is mentally disabled. |
|
Exclusion criteria
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
None |
|
Number of arms
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
3 |
|
Funding
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Universidade Federal do Ceara |
|
Inclusion age min
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
18 |
|
Inclusion age max
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
60 |
|
Countries
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Brazil |
|
Type of patients
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Mild/moderate disease at enrollment |
|
Severity scale
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
2: Mild/moderate disease at enrollment |
|
Total sample size
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
219 |
|
primary outcome
Last imported at : July 8, 2021, 4 a.m. Source : ClinicalTrials.gov |
The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1 or 2 on the four-category ordinal scale. [Time Frame: Day 7 follow up after enrollment.] |
|
Notes
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
None |
|
Phase
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
Phase 3 |
|
Arms
Last imported at : June 18, 2021, 12:32 a.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 2207, "treatment_name": "Bromhexine hydrochloride+n-acetylcysteine", "treatment_type": "Respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 850, "treatment_name": "N-acetylcysteine", "treatment_type": "Respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1369, "treatment_name": "Vitamin c", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}] |